TD Cowen has increased its price target on Revvity Inc (NYSE: RVTY) to $124.00 from $120.00, while continuing to carry a Buy recommendation on the life sciences and diagnostics company.
The new $124 target equates to about a 15% premium relative to Revvity's recent trading price of $107.94. TD Cowen's raise is a roughly 3.3% boost over its previous target and was disclosed in a research note from analyst Dan Brennan dated Tuesday, February 03, 2026.
TD Cowen's move aligns with data indicating several analysts have recently raised their earnings expectations for the company - with five analysts noted as having revised estimates upward.
Revvity, which operates in instruments, consumables and services for the pharmaceutical, biotechnology and research markets and previously traded under the PerkinElmer name, reported fourth-quarter 2025 results that topped consensus forecasts. The company posted adjusted earnings per share of $1.70 versus a projected $1.55, and revenue of $772 million compared with an expected $758.53 million.
Despite those stronger-than-expected results, Revvity's shares experienced a decline in pre-market trading following the release. Market reaction has been tempered even as some research firms reiterated positive views. KeyBanc, for example, has reiterated an Overweight rating and maintained a $125.00 price target.
Analysts and investors appear to be weighing the company's solid quarterly performance against Revvity's fiscal 2026 guidance for organic growth of 2-3%, which is lower than growth rates cited by some industry peers. Those dynamics have contributed to what observers describe as mixed sentiment around the stock.
The continued Buy and Overweight recommendations from TD Cowen and KeyBanc underscore ongoing confidence among some sell-side analysts, while the modest organic growth outlook and the stock's immediate market reaction highlight areas of investor caution.
Context summary
- TD Cowen raised its price target to $124 from $120 and kept a Buy rating; the change was communicated by analyst Dan Brennan on February 03, 2026.
- Revvity beat fourth-quarter 2025 EPS and revenue estimates, with adjusted EPS of $1.70 and revenue of $772 million.
- KeyBanc reiterated an Overweight rating with a $125.00 target; Revvity's fiscal 2026 organic growth guidance of 2-3% is lower than some peers, contributing to mixed investor sentiment.